HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe
© 2023 British HIV Association..
BACKGROUND: To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort.
METHODS: We performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID-19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID-19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1.
RESULTS: The majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID-19 diagnosis was 605 cells/μL [interquartile range (IQR) 409-824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/μL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001).
CONCLUSION: We can conclude that detectable HIV viral load was an independent risk factor for severe COVID-19 illness and can be used as a prognostic indicator in this cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
HIV medicine - 25(2024), 3 vom: 28. März, Seite 343-352 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oprea, Cristiana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD4 cell count |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 06.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13578 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365059684 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365059684 | ||
| 003 | DE-627 | ||
| 005 | 20240306232551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13578 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM365059684 | ||
| 035 | |a (NLM)38014768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oprea, Cristiana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British HIV Association. | ||
| 520 | |a BACKGROUND: To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort | ||
| 520 | |a METHODS: We performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID-19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID-19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1 | ||
| 520 | |a RESULTS: The majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID-19 diagnosis was 605 cells/μL [interquartile range (IQR) 409-824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/μL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001) | ||
| 520 | |a CONCLUSION: We can conclude that detectable HIV viral load was an independent risk factor for severe COVID-19 illness and can be used as a prognostic indicator in this cohort | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD4 cell count | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV viral load strata | |
| 650 | 4 | |a PLWH | |
| 650 | 4 | |a outcomes | |
| 700 | 1 | |a Quirke, Siobhan |e verfasserin |4 aut | |
| 700 | 1 | |a Ianache, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Bursa, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniak, Sergii |e verfasserin |4 aut | |
| 700 | 1 | |a Bogdanic, Nikolina |e verfasserin |4 aut | |
| 700 | 1 | |a Vassilenko, Anne I |e verfasserin |4 aut | |
| 700 | 1 | |a Aimla, Kersti |e verfasserin |4 aut | |
| 700 | 1 | |a Matulionyte, Raimonda |e verfasserin |4 aut | |
| 700 | 1 | |a Rukhadze, Nino |e verfasserin |4 aut | |
| 700 | 1 | |a Harxhi, Arjan |e verfasserin |4 aut | |
| 700 | 1 | |a Fleischhans, Lukáš |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Botond |e verfasserin |4 aut | |
| 700 | 1 | |a Sedlacek, Dalibor |e verfasserin |4 aut | |
| 700 | 1 | |a Dragovic, Gordana |e verfasserin |4 aut | |
| 700 | 1 | |a Verhaz, Antonija |e verfasserin |4 aut | |
| 700 | 1 | |a Yancheva, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Acet, Oguzhan |e verfasserin |4 aut | |
| 700 | 1 | |a Protopapas, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalska, Justyna Dominika |e verfasserin |4 aut | |
| 700 | 0 | |a Euroguidelines in Central and Eastern Europe Network Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 25(2024), 3 vom: 28. März, Seite 343-352 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:28 |g month:03 |g pages:343-352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13578 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 28 |c 03 |h 343-352 | ||